India's top court to hear Glivec patent case from September 11
(Reuters) - India's top court will hear final arguments from September 11 in a key patent dispute between Swiss drugmaker Novartis and India's patent office, a case that could curb India's global position as a supplier of cut-price generic medicines.
The hearing, which is expected to last for at least two months, had been scheduled to being on Wednesday.
Novartis appealed to the Supreme Court after its cancer medicine Glivec was refused a patent on the grounds the drug is not a new molecule but an amended version of a known compound. Novartis has challenged this clause of Indian Patents Act.
The case has further built tensions between the Big Pharma and India, following a decision by the patent office in March to strip Germany's Bayer AG of its exclusive right to sell another costly cancer drug, Nexavar.
Western firms see huge potential in India's rapidly growing economy but are concerned over safety of intellectual property.
The case is of immense importance to Novartis as it needs certainty of laws if further investments are to be planned.
"The patent for Glivec is not really the issue here. It is just an example of us wanting very clear legal clarity about what kind of innovation is patentable," Paul Herrling, head of the Novartis Institute for Tropical Diseases, told Reuters earlier.
(Reporting by Kaustubh Kulkarni in MUMBAI; Editing by Alex Richardson)
- Tweet this
- Share this
- Digg this
- Russia can run on empty for a year if sanctions block new bonds
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Mumbai hit by big power cuts after technical glitch at Tata Power unit
- Rupee sees biggest fall in three weeks on broad dollar gains
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
The world's "disastrously inadequate response" to West Africa's Ebola outbreak means many people are dying who could easily be saved, the head of the World Bank said on Monday, as Nigeria confirmed another case of the highly contagious virus. Full Article